Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:RARENASDAQ:SWTXNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$68.10+2.8%$61.34$47.86▼$107.37$3.75B0.28604,849 shs595,314 shsRAREUltragenyx Pharmaceutical$37.17+0.7%$35.58$29.59▼$60.37$3.51B0.25841,876 shs930,291 shsSWTXSpringWorks Therapeutics$46.80$43.41$28.21▼$62.00$3.53B0.72.29 million shs3.12 million shsSYRESpyre Therapeutics$16.97+2.1%$14.23$10.91▼$40.26$1.02B2.72614,596 shs309,214 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%+7.13%+17.88%-5.57%+34.11%RAREUltragenyx Pharmaceutical0.00%+9.74%+5.72%-0.88%-10.22%SWTXSpringWorks Therapeutics0.00%+0.17%+1.17%-3.39%+16.36%SYRESpyre Therapeutics0.00%+11.28%+20.35%-9.01%-49.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.0179 of 5 stars3.51.00.00.02.92.50.0RAREUltragenyx Pharmaceutical3.9281 of 5 stars3.51.00.03.82.82.50.6SWTXSpringWorks Therapeutics1.4735 of 5 stars3.12.00.00.02.40.00.6SYRESpyre Therapeutics2.2636 of 5 stars3.61.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.3363.49% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$88.77138.82% UpsideSWTXSpringWorks Therapeutics 2.13Hold$52.5712.33% UpsideSYRESpyre Therapeutics 3.25Buy$53.40214.67% UpsideCurrent Analyst Ratings BreakdownLatest SYRE, SWTX, RARE, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/12/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.005/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.005/5/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.004/30/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$74.00 ➝ $47.004/29/2025SWTXSpringWorks TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold4/29/2025SWTXSpringWorks TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$66.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$77.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2025SWTXSpringWorks TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$63.00 ➝ $47.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M48.86N/AN/A$9.97 per share6.83RAREUltragenyx Pharmaceutical$590.69M5.95N/AN/A$2.76 per share13.47SWTXSpringWorks Therapeutics$219.67M16.05N/AN/A$10.01 per share4.68SYRESpyre Therapeutics$890K1,149.31N/AN/A($0.22) per share-77.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%8/14/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-101.60%-193.80%-38.15%7/30/2025 (Estimated)SWTXSpringWorks Therapeutics-$325.10M-$3.41N/AN/AN/A-134.73%-46.74%-41.12%8/6/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$3.77N/AN/AN/AN/A-210.01%-44.40%8/6/2025 (Estimated)Latest SYRE, SWTX, RARE, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SWTXSpringWorks Therapeutics-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025Q1 2025SYRESpyre Therapeutics-$0.76-$0.74+$0.02-$0.74N/AN/A5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29RAREUltragenyx PharmaceuticalN/A2.372.65SWTXSpringWorks TherapeuticsN/A6.166.02SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%RAREUltragenyx Pharmaceutical97.67%SWTXSpringWorks TherapeuticsN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%RAREUltragenyx Pharmaceutical5.50%SWTXSpringWorks Therapeutics7.83%SYRESpyre Therapeutics15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.70 millionOptionableRAREUltragenyx Pharmaceutical1,31094.54 million86.99 millionOptionableSWTXSpringWorks Therapeutics23075.35 million68.73 millionOptionableSYRESpyre Therapeutics7360.28 million48.24 millionOptionableSYRE, SWTX, RARE, and ACLX HeadlinesRecent News About These CompaniesSpyre Therapeutics Announces Grants of Inducement AwardsJune 6 at 4:05 PM | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - Here's What HappenedJune 4, 2025 | marketbeat.com122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbHJune 3, 2025 | marketbeat.comWellington Management Group LLP Has $37.35 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 1, 2025 | marketbeat.comMillennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 31, 2025 | marketbeat.comAnalysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $53.40May 31, 2025 | americanbankingnews.comWall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should KnowMay 30, 2025 | zacks.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Voloridge Investment Management LLCMay 29, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsMay 29, 2025 | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 28, 2025 | prnewswire.comBNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 27, 2025 | marketbeat.comWoodline Partners LP Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 25, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust CorpMay 21, 2025 | marketbeat.comRTW Investments LP Raises Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 18, 2025 | marketbeat.comProsight Management LP Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 17, 2025 | marketbeat.comJanus Henderson Group PLC Buys 336,209 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 16, 2025 | marketbeat.comHow Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%May 13, 2025 | zacks.comJefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 13, 2025 | marketbeat.comFirst Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsKeep Your EYE on This Stock, It Just Got a Rare Double UpgradeBy Sam Quirke | May 15, 2025View Keep Your EYE on This Stock, It Just Got a Rare Double UpgradeSYRE, SWTX, RARE, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$68.10 +1.85 (+2.79%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$69.88 +1.78 (+2.61%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Ultragenyx Pharmaceutical NASDAQ:RARE$37.17 +0.26 (+0.70%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$37.35 +0.18 (+0.48%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.SpringWorks Therapeutics NASDAQ:SWTX$46.80 0.00 (0.00%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$46.86 +0.07 (+0.14%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Spyre Therapeutics NASDAQ:SYRE$16.97 +0.35 (+2.11%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$16.93 -0.04 (-0.24%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
